## Helena Persson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3815340/publications.pdf

Version: 2024-02-01

759233 610901 27 616 12 24 h-index citations g-index papers 30 30 30 1083 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	CDR-H3 Diversity Is Not Required for Antigen Recognition by Synthetic Antibodies. Journal of Molecular Biology, 2013, 425, 803-811.	4.2	150
2	A Focused Antibody Library for Improved Hapten Recognition. Journal of Molecular Biology, 2006, 357, 607-620.	4.2	83
3	Targeting HER2 + breast cancer cells: Lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles. Journal of Controlled Release, 2013, 172, 395-404.	9.9	47
4	Generation and analyses of human synthetic antibody libraries and their application for protein microarrays. Protein Engineering, Design and Selection, 2016, 29, 427-437.	2.1	35
5	Antibody Heavy Chain Variable Domains of Different Germline Gene Origins Diversify through Different Paths. Frontiers in Immunology, 2017, 8, 1433.	4.8	34
6	Combination of novel HER2â€targeting antibody 1E11 with trastuzumab shows synergistic antitumor activity in HER2â€positive gastric cancer. Molecular Oncology, 2015, 9, 398-408.	4.6	31
7	Delineating the specificity of an IgE-encoding transcriptome. Journal of Allergy and Clinical Immunology, 2007, 120, 1186-1192.	2.9	26
8	A Multicenter Trial Defining a Serum Protein Signature Associated with Pancreatic Ductal Adenocarcinoma. International Journal of Proteomics, 2015, 2015, 1-10.	2.0	26
9	Plasma protein profiling in a stage defined pancreatic cancer cohort – Implications for early diagnosis. Molecular Oncology, 2016, 10, 1305-1316.	4.6	25
10	In vitro evolution of an antibody fragment population to find high-affinity hapten binders. Protein Engineering, Design and Selection, 2008, 21, 485-493.	2.1	20
11	A common idiotype in IgE and its relation to recognition of the grass pollen allergen Phl p 2. Molecular Immunology, 2008, 45, 2715-2720.	2.2	16
12	Combination of phage and Gram-positive bacterial display of human antibody repertoires enables isolation of functional high affinity binders. New Biotechnology, 2018, 45, 80-88.	4.4	14
13	In Vitro Evolution of Antibodies Inspired by In Vivo Evolution. Frontiers in Immunology, 2018, 9, 1391.	4.8	13
14	Generation and validation of recombinant antibodies to study human aminoacyl-tRNA synthetases. Journal of Biological Chemistry, 2020, 295, 13981-13993.	3.4	13
15	Fed-batch production assessment of a tetravalent bispecific antibody: A case study on piggyBac stably transfected HEK293 cells. New Biotechnology, 2021, 65, 9-19.	4.4	12
16	Circulating Levels of Interferon Regulatory Factor-5 Associates With Subgroups of Systemic Lupus Erythematosus Patients. Frontiers in Immunology, 2019, 10, 1029.	4.8	11
17	Antibody Validation by Immunoprecipitation Followed by Mass Spectrometry Analysis. Methods in Molecular Biology, 2017, 1575, 175-187.	0.9	10
18	Selection and structural characterization of anti-TREM2 scFvs that reduce levels of shed ectodomain. Structure, 2021, 29, 1241-1252.e5.	3.3	9

#	Article	IF	CITATIONS
19	Advancing the immunoaffinity platform AFFIRM to targeted measurements of proteins in serum in the pg/ml range. PLoS ONE, 2018, 13, e0189116.	2.5	7
20	Longitudinal assessment of reactivity and affinity profile of anti-Jo1 autoantibodies to distinct HisRS domains and a splice variant in a cohort of patients with myositis and anti-synthetase syndrome. Arthritis Research and Therapy, 2022, 24, 62.	3.5	7
21	AFFIRM—A Multiplexed Immunoaffinity Platform That Combines Recombinant Antibody Fragments and LC-SRM Analysis. Journal of Proteome Research, 2014, 13, 5837-5847.	3.7	6
22	Exploring central and peripheral diversity in antibody evolution. Molecular Immunology, 2007, 44, 2729-2736.	2.2	5
23	Development of Phage-Based Antibody Fragment Reagents for Affinity Enrichment of Bacterial Immunoglobulin G Binding Proteins. Journal of Proteome Research, 2015, 14, 4704-4713.	3.7	5
24	Tumor localized agonistic anti-CD40 therapy and beyond. Expert Opinion on Biological Therapy, 2020, 20, 215-217.	3.1	5
25	Charges drive selection of specific antibodies by phage display. Journal of Immunological Methods, 2010, 353, 24-30.	1.4	2
26	Advancing the global proteome survey platform by using an oriented single chain antibody fragment immobilization approach. New Biotechnology, 2016, 33, 503-513.	4.4	1
27	An Adaptable Antibodyâ€Based Platform for Flexible Synthetic Peptide Delivery Built on Agonistic CD40 Antibodies. Advanced Therapeutics, 0, , 2200008.	3.2	0